Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2008

View Archived Issues

Wyeth initiates phase IIIb INTORACT study comparing Torisel plus Avastin for RCC

AstraZeneca submits sNDA to the FDA for Nexium I.V. for injection in peptic ulcer bleeding

FolateImmune regimen active, well tolerated in metastatic renal cell carcinoma

Antitumor activity seen with anti-AGS-16 antibody in vivo

Phase I studies assess effects of TKI-258 on biomarkers in patients with AML, melanoma

GSK completes tender offer for shares of Sirtris

Genentech initiates phase Ib clinical trial of SGN-40 in combination with Velcade

Mentor completes enrollment in phase I study of botulinum toxin type A for cervical dystonia

ThromboGenics and BioInvent report positive results from phase I study of TB-403

Amgen describes novel compounds to treat hyperparathyroidism in recent patent

Pomalidomide data presented at ASCO

Three phase I studies of anticancer agent PR-104 reported

NN-7128 phase I trial completed

Enrollment completed in phase III study of JZP-6 for fibromyalgia

Fast track designation for LX-1032 in carcinoid syndrome

Sepracor completes acquisition of Oryx

Celgene withdraws European MAA for lenalidomide

Critical Therapeutics reports positive results from phase II clinical trial of zileuton injection

New treatment options for diabetic nephropathy imparted in recent Kowa patent

Hemispherx completes enrollment in phase II study of Ampligen as seasonal flu vaccine enhancer

Novel diagnostic agents disclosed in recent patent

Abbott submits application in Japan for Xience V everolimus eluting coronary stent system

Arana and Greenovation enter collaboration agreement to develop anticancer antibodies

FDA grants approval to Bradmer to initiate phase III GLASS-ART trial of Neuradiab in GBM

Novacea presents preliminary findings from of ASCENT-2 data analysis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...